Literature DB >> 9971765

Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III.

S Koseki1, T Tanabe, K Tani, S Asano, T Shioda, Y Nagai, T Shimada, J Ohkawa, K Taira.   

Abstract

In order to determine the parameters that govern the activity of a ribozyme in vivo, we made a systematic analysis of chimeric tRNAVal ribozymes by measuring their cleavage activities in vitro as well as the steady-state levels of transcripts, the half-lives of transcribed tRNAVal ribozymes, and their activities in both HeLa and H9 cells. These analyses were conducted by the use of transient expression systems in HeLa cells and stable transformants that express ribozymes. Localization of transcripts appeared to be determined by the higher-order structure of each transcribed tRNAVal ribozyme. Since colocalization of the ribozyme with its target RNA is important for strong activity of the ribozyme in vivo, the best system for tRNA-based expression seems to be one in which the structure of the transcript is different from that of the natural tRNA precursor so that processing of the tRNAVal ribozyme can be avoided. At the same time, the structure of the transcript must be similar enough to allow recognition, probably by an export receptor, so that the transcript can be exported to the cytoplasm to ensure colocalization with its target. In the case of several tRNAVal ribozymes that we constructed, inspection of computer-predicted secondary structures enabled us to control the export of transcripts. We found that only a ribozyme that was transcribed at a high level and that had a sufficiently long half-life, within cells, had significant activity when used to withstand a challenge by human immunodeficiency virus type 1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9971765      PMCID: PMC104427     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  The Hydrolysis of RNA: From Theoretical Calculations to the Hammerhead Ribozyme-Mediated Cleavage of RNA.

Authors:  De-Min Zhou; Kazunari Taira
Journal:  Chem Rev       Date:  1998-05-07       Impact factor: 60.622

Review 2.  RNA enzymes (ribozymes) as antiviral therapeutic agents.

Authors:  J J Rossi; N Sarver
Journal:  Trends Biotechnol       Date:  1990-07       Impact factor: 19.536

3.  Quantitative determination of deleted mitochondrial DNA relative to normal DNA in parkinsonian striatum by a kinetic PCR analysis.

Authors:  T Ozawa; M Tanaka; S Ikebe; K Ohno; T Kondo; Y Mizuno
Journal:  Biochem Biophys Res Commun       Date:  1990-10-30       Impact factor: 3.575

4.  Ribozymes as potential anti-HIV-1 therapeutic agents.

Authors:  N Sarver; E M Cantin; P S Chang; J A Zaia; P A Ladne; D A Stephens; J J Rossi
Journal:  Science       Date:  1990-03-09       Impact factor: 47.728

5.  Construction of a novel RNA-transcript-trimming plasmid which can be used both in vitro in place of run-off and (G)-free transcriptions and in vivo as multi-sequences transcription vectors.

Authors:  K Taira; K Nakagawa; S Nishikawa; K Furukawa
Journal:  Nucleic Acids Res       Date:  1991-10-11       Impact factor: 16.971

6.  Targeted and highly efficient gene transfer into CD4+ cells by a recombinant human immunodeficiency virus retroviral vector.

Authors:  T Shimada; H Fujii; H Mitsuya; A W Nienhuis
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

7.  A small catalytic oligoribonucleotide.

Authors:  O C Uhlenbeck
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

8.  Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication.

Authors:  B A Sullenger; T C Lee; C A Smith; G E Ungers; E Gilboa
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

9.  Role of divalent metal ions in the hammerhead RNA cleavage reaction.

Authors:  S C Dahm; O C Uhlenbeck
Journal:  Biochemistry       Date:  1991-10-01       Impact factor: 3.162

10.  Inhibition of SV40 replicon function by engineered antisense RNA transcribed by RNA polymerase III.

Authors:  P A Jennings; P L Molloy
Journal:  EMBO J       Date:  1987-10       Impact factor: 11.598

View more
  18 in total

1.  Reduction of target gene expression by a modified U1 snRNA.

Authors:  S A Beckley; P Liu; M L Stover; S I Gunderson; A C Lichtler; D W Rowe
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

2.  Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells.

Authors:  T Kuwabara; M Warashina; S Koseki; M Sano; J Ohkawa; K Nakayama; K Taira
Journal:  Nucleic Acids Res       Date:  2001-07-01       Impact factor: 16.971

3.  RNA-protein hybrid ribozymes that efficiently cleave any mRNA independently of the structure of the target RNA.

Authors:  M Warashina; T Kuwabara; Y Kato; M Sano; K Taira
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-08       Impact factor: 11.205

4.  A triplex ribozyme expression system based on a single hairpin ribozyme.

Authors:  Guillermo Aquino-Jarquin; María Luisa Benítez-Hess; Joseph A DiPaolo; Luis M Alvarez-Salas
Journal:  Oligonucleotides       Date:  2008-09

Review 5.  Relieving bottlenecks in RNA drug discovery for retinal diseases.

Authors:  Jack M Sullivan; Edwin H Yau; R Thomas Taggart; Mark C Butler; Tiffany A Kolniak
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

6.  tRNAVal-heterodimeric maxizymes with high potential as geneinactivating agents: simultaneous cleavage at two sites in HIV-1 Tat mRNA in cultured cells.

Authors:  T Kuwabara; M Warashina; A Nakayama; J Ohkawa; K Taira
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

7.  Targeting mortalin using conventional and RNA-helicase-coupled hammerhead ribozymes.

Authors:  Renu Wadhwa; Hiroshi Ando; Hiroaki Kawasaki; Kazunari Taira; Sunil C Kaul
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

8.  Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy.

Authors:  Heba E Abdelmaksoud; Edwin H Yau; Michael Zuker; Jack M Sullivan
Journal:  Exp Eye Res       Date:  2008-12-06       Impact factor: 3.467

9.  Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles.

Authors:  Victor M Miller; Cynthia M Gouvion; Beverly L Davidson; Henry L Paulson
Journal:  Nucleic Acids Res       Date:  2004-01-30       Impact factor: 16.971

10.  Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells.

Authors:  Hiroaki Kawasaki; Kazunari Taira
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.